



Dear Friend,

Together, We CAN Change Childhood Cancer Outcomes

The Sarcoma Alliance for Research Through Collaboration (SARC) drives collaborations among researchers at close to one hundred of the leading academic medical centers in the United States and internationally.

SARC, a 501(c)(3) non-profit public charity founded in 2003, and our partners are committed to discovering, developing, and delivering the latest and most promising treatments for all types of sarcomas. Unfortunately, sarcomas are relatively prevalent in childhood cancers, being found in one out of every five pediatric cancers. In adults, sarcomas are less common--representing one out of every one hundred cancer patients.

Building upon SARC's collaborating academic institutions' strengths with sarcoma expertise, SARC brings together researchers, patients, data, biospecimens, and knowledge. The goal is to overcome barriers to meaningful scientific progress via laboratory research, with SARC's expert staff centrally managing clinical trials in both pediatric and adult sarcomas.

Unlike most cancer foundations, SARC directly develops, sponsors, and manages the research projects rather than simply providing funding support. The following pages include a **Case Statement** that summarizes SARC's current and planned programs and initiatives to advance scientific discoveries to benefit sarcoma patients.

Below is just a sampling of SARC's achievements in 2021, which were only possible with support from donors like you:

1. Scientific and Clinical Leadership:


- a. We created and filled the new role of Chief Scientific Officer (CSO), charged with expanding SARC commitments in sarcoma biology, discovery science, and biomarkers while strengthening its existing portfolio of clinical trials to shed light on **why new therapies help some people and not others**, thereby reducing needless treatment toxicities.
- b. Renewed and expanded SARC's "crown jewel" Career Development Program. By investing in young physician/scientific talent today, we are **recruiting and cultivating tomorrow's leaders** in the fight to defeat sarcoma—an especially acute need for an uncommon cancer with limited career paths. Past SARC award recipients are among today's most productive sarcoma researchers, driving, translating, and accelerating discoveries and innovations to benefit patients.

2. Clinical trials (<https://sarctrials.org/sarc-clinical-trials/>): SARC **launched three new clinical drug trials**, each focused on innovative drugs and combinations—adding to the four SARC-sponsored and -directed clinical trials already underway. SARC has completed 21 clinical trials, including two which achieved patient enrollment targets in 2021. Results of all trials are shared with the scientific and patient communities without delay.
3. Patient Engagement, Education, and Awareness:
 - a. Appointed two new members from the sarcoma patient advocacy community to SARC's Board of Directors, **bringing the patient and caregiver voices to oversight and governance.**
 - b. Developed and released the first in a planned series of **patient-focused educational tools** termed the Animated Patient. The inaugural release focused on adoptive cell therapy for sarcoma, a type of cancer treatment that uses the patient's immune system to treat their specific cancer.
 - c. Published a white paper in the Journal of Oncology Navigation and Survivorship, the outcome of a partnership between the Epithelioid Sarcoma (ES) Collaborative and SARC. "Increasing awareness and understanding of soft tissue sarcoma among patients and providers may be the **first step to decreasing the time to a correct diagnosis**, reducing barriers to timely treatment and access to experienced sarcoma centers," says Maria Voermans, an ES survivor and advocate who is an author of the white paper.


Please review the following Case Statement—we are **asking for your support** to help SARC continue to advance its mission to improve the lives and outcomes of those impacted by sarcoma: <https://sarctrials.org/donate/donation-form/>.

Please contact me if you'd like to discuss opportunities or have any questions. I greatly appreciate your thoughtful consideration.

Thank you,



Steven Young
President & CEO
Telephone (direct line): (203) 226-5765
Email: syoung@sarctrials.org



SARC

collaborating to cure sarcoma



DRIVING SARCOMA RESEARCH TO ACHIEVE A CURE
A CASE STATEMENT FOR FINANCIAL SUPPORT



Together **We** Can Change Patient Outcomes

SARC's mission is to connect individuals and organizations from around the world committed to discovering, developing, and delivering the latest and most promising treatments for Sarcoma.

The Sarcoma research, clinical, and patient communities are geographically scattered and under-resourced. It is essential to share scientific knowledge and advance research for improved treatments to defeat Sarcoma.

Simply put, SARC drives high-impact, centrally-supported collaborations among the Sarcoma research community.

The Sarcoma field is small, and the need for fostered collaborations is critical. We can help improve patient outcomes and ultimately achieve a cure with your support.



**PRESIDENT &
CHIEF EXECUTIVE OFFICER**

STEVEN W. YOUNG



What are **Sarcomas**?


Sarcomas are a heterogeneous group of cancers that arise anywhere in the body in the connective and musculoskeletal tissues.

Sarcomas are uncommon and there are many different types — experts have identified more than 80 different forms — leading to significant diagnostic and therapeutic challenges.

Sarcomas represent 15 to 20% of childhood cancers and 1% of adult cancers.

Sarcomas are more prevalent in young individuals — 15% to 20% of childhood cancers

About SARC



SARC (Sarcoma Alliance for Research Through Collaboration) is a U.S.-based 501(c)(3) non-profit cancer research organization which leads domestic and international collaborative discovery, translational research, and clinical trials in Sarcoma.

SARC is dedicated to fostering progress in the treatment of Sarcoma to improve patient outcomes and ultimately find a cure.

SARC is one of the few organizations focusing on all types of Sarcoma.

SARC was formed in 2003 by the Sarcoma research community to bring together

the best cancer centers and researchers in the world.

Among other accomplishments, SARC has completed 21 innovative clinical trials, with 6 more underway.

SARC's unique ability to promote collaboration and unity among the leading Sarcoma researchers ensures that **“things get done.”**

The **only** non-profit solely focused on achieving scientific breakthroughs in the treatment of Sarcoma, and ultimately finding a cure



Our Mission

To provide a collaborative infrastructure facilitating and accelerating progress in the diagnosis and treatment of Sarcoma to improve outcomes for affected patients.

Our Strategy

Build upon strengths of centers with Sarcoma expertise. Bring together researchers, patients, data, biospecimens, and knowledge to overcome barriers to meaningful scientific progress. Support laboratory research and clinical trials in both pediatric and adult Sarcomas.



SARC Organizational Milestones

- **2003** Founded by Sarcoma researchers
Launched first clinical trial
- **2009** Launched Career Development Program
 - Recruiting scientific talent needed to achieve/accelerate high-impact advancesSARC011
 - 1st international clinical trial
- **2012** Awarded five-year Sarcoma SPORE by National Institutes of Health
 - 1st such award in any cancer type that connected multiple cancer centers to work collaboratively
- **2014** SARC021
 - 1st Phase III trial (more than 100 centers)SARC024
 - 1st active systemic therapy in metastatic Osteosarcoma in 30 years
- **2017** SARC028
 - 1st study to test immune checkpoint inhibitors in advanced Sarcoma
- **2018** Helped Establish Sarcoma Coalition
 - Sarcoma patient advocacy foundations working together
- **2020** Formed SARC Research Advocacy Council
- **2021** Chief Scientific Officer position established
Launched three new clinical trials
Launched Animated Patient educational series
- **2022** EORTC (pan-European group) analysis of multiple SARC trials to understand chemotherapy response in more common Sarcomas
SARC042
 - Selecting for patients most likely to respond based on their immune signatures

Catalyzing Scientific and Clinical Progress



Jonathan Fletcher, MD
SARC Chief Scientific Officer

Associate Professor,
Harvard Medical School

Brigham and Women's
Hospital

Dana Farber/Harvard
Cancer Center

A Scientist's Perspective: Why is SARC Needed?

Given the rarity of Sarcoma and the many subtypes, no single institution has sufficient patient resources for timely accrual and adequate statistical power to complete trials that will yield meaningful results for a variety of Sarcomas.


SARC fosters collaborations among the best minds in the Sarcoma field, drawing upon resources at different research institutions in the U.S. and globally. SARC is committed to:

- recruiting, supporting, and mentoring tomorrow's Sarcoma leaders,
- understanding why new therapies help some people and not others, thereby reducing needless treatment toxicity, and
- identifying and evaluating drugs that target essential biologic functions in Sarcoma.

These and other ground-breaking SARC programs are needed to develop effective therapies for Sarcoma patients.

Thank you for your investment driving science to patients!

Progress against Sarcoma demands a “**team science**” approach



Bridging Sarcoma Research Centers



Facilitating translational **research** that otherwise would be unfeasible

How Can You Best Help?


Operating Funds Needed

SARC has been the fortunate recipient of program-related restricted funding, but our ability to continue to operate requires general operating support in the future.

The lessons of the ongoing pandemic have shown that a solid infrastructure is necessary to weather current challenges so we can succeed in the face of future disruptors and plan for a sustainable future.

SARC incurs expenses that are not covered by grants and contracts.

Unrestricted Funds Balance



2022 Goal
\$400,000
(unrestricted support—
every dollar supports our
mission delivery)

2022 Budget: \$4.6M (76% Programs • 24% Operations)

Investing in the **Future** of Sarcoma Research

PROGRAM 1

SARC CAREER DEVELOPMENT AWARDS (CDA) — RECRUITING & MENTORING RESEARCHERS

Generally acknowledged as among SARC’s “Crown Jewels,” a core program of SARC has been to foster development of innovative research via the cultivation of the ideas and career paths of early-stage, young physicians /scientists dedicated to defeating Sarcoma.

This program represents an essential and critical investment

in scientific talent to advance research, an especially acute need for an uncommon cancer with limited career paths.

Past SARC award recipients are among today’s most productive Sarcoma researchers, driving discoveries and translating innovations to the benefit of patients.

2022 Goal
\$400,000

(two awardees, including a second year of support contingent on scientific progress)



Achieving meaningful progress against an uncommon cancer depends on **investing** in young talent today to cultivate tomorrow’s leaders

Investing in the **Future** of Sarcoma Research

PROGRAM 1

CAREER DEVELOPMENT AWARDEES

The program identifies, recruits, and fosters promising investigators from diverse scientific backgrounds to become translational researchers in Sarcoma. Without such support, uncommon cancers would struggle to attract the talent to make scientific and clinical progress.

Here's just a sampling of unsolicited testimonials from past awardees:

“The SARC CDA supported my early interest in Sarcoma research, giving me the flexibility to develop and investigate new Sarcoma treatment options. SARC has been instrumental in my enduring dedication to advancing Sarcoma research.”



Lara Davis, MD
Associate Professor of Medicine,
Sarcoma Program Director,
Co-Leader, Knight Cancer Institute
Translational Oncology Program,
Oregon Health & Sciences University

“If I had to pick a single event that has enabled my dedication to Sarcoma research, that would be obtaining the SARC CDA award.”



Adrian Marino-Enriquez, MD, PhD
Scientist, Brigham and Women's Hospital;
Assistant Professor of Pathology,
Harvard Medical School

“I owe everything to SARC for early support.”



Brian Van Tine, MD, PhD
Professor of Medicine,
Sarcoma Program Director,
Department of Pediatrics,
Washington University School of Medicine,
St. Louis

YEAR	SUPPORTED RESEARCHER	CURRENT INSTITUTION (2022)
2009	Sandra Strauss MD, PhD	University College Hospital, London
2009	Joseph Ludwig MD	MD Anderson Cancer Center
2010	Joshua Schifman MD	University of Utah
2010	Patrick Grohar MD, PhD	Children's Hospital of Philadelphia
2011	Keila Torres MD, PhD	MD Anderson Cancer Center
2011	Seth Pollack MD, PhD	Northwestern University
2012	Brian Van Tine MD, PhD	Washington University School of Medicine
2012	Adrian Marino-Enriquez MD, PhD	Brigham and Women's Hospital; Harvard Medical School
2013	Cigall Kadoch PhD	Dana-Farber Cancer Institute; Broad Institute of Harvard and Massachusetts Institute of Technology
2013	John Shern MD	National Cancer Institute
2013	Simone Hettmer MD	University Medical Center, Germany
2014	James Chen MD	The Ohio State University
2014	David Liebner MD	The Ohio State University
2014	Armelle Dufresne MD, PhD	Centre Leon Berard, France
2014	Cesar Serrano-Garcia MD	Vall d'Hebron Institute of Oncology, Spain
2015	David Van Mater MD, PhD	Duke University Medical Center
2015	Masanori Hayashi MD	Colorado University School of Medicine
2016	Lara Davis MD	Oregon Health & Science University
2016	Angela Hirbe MD, PhD	Washington University School of Medicine
2017	Robbie Majzner MD	Stanford University School of Medicine
2018	Anusha Kalbasi MD	University of California, Los Angeles
2019	Inga-Marie Schaefer MD	Brigham and Women's Hospital, Harvard Medical School

Investing in the **Future** of Sarcoma Research

PROGRAM 2

INNOVATIVE CLINICAL TRIALS – LINKING TISSUE & BLOOD “BIOMARKER” RESEARCH TO PATIENT OUTCOMES

SARC has sponsored and launched 27 clinical trials since our founding.

Many of SARC’s more recent trials have included “correlative sciences,” which illuminates the relationship between the patients’ cancer cell biology (biomarkers) to disease progression or clinical responses. This is the promise of precision (or personalized) medicine. Unfortunately, limited trial budgets can curtail these highly informative, predictive studies.

2022 Goal

\$200,000

(adding biomarker analyses to three open and soon to launch SARC-sponsored clinical trials)



Biomarkers: used to see how well the body responds to a treatment for a disease or condition

Correlative Science: helps identify which patients are most likely to benefit from specific treatments

Investing in the **Future** of Sarcoma Research

PROGRAM 3

SARC & SARCOMA PATIENT ADVOCACY — ENGAGING PATIENTS, FAMILIES & CAREGIVERS

Sarcoma advocacy is integral to the mission of SARC and to our community, building awareness of Sarcoma treatments, clinical trials, and resources that are available to help patients and families.

SARC's Research Advocacy Council is an evolving, specially trained group of Sarcoma survivors and caregivers. Our goal for 2022 and beyond is to assign a Research Advocate to each SARC clinical trial and so work side-by-side with the physicians adding the patient

voice into study ideation and design—enabling more patient-centric studies, increased enrollment, and greater impact.

Further, SARC intends to send Research Advocates to the major oncology/ Sarcoma conferences. They will capture and then communicate (in lay language) promising scientific advances via SARC's social media platforms—thus bringing hope and knowledge home to patients and their families.

2022 Goal
\$100,000

(patient voice to research studies; bring scientific advances home to patient community)

Communicate scientific and clinical advances to **bring hope home** to the patient and caregiver communities

Investing in the **Future** of Sarcoma Research

PROGRAM 4

SARC EDUCATION AND CONFERENCES — BUILDING BRIDGES / CONNECTING SILOS

One of the most effective ways to advance knowledge is to bring scientists together to share their work and findings.

SARC's scientific/membership meetings have long provided forums for Sarcoma collaborators to gather, present and discuss research, share insights and discoveries, spark ideas, and so inspire new directions for SARC and our collaborators to pursue.

- June: American Society of Clinical Oncology
- November: Connective Tissue Oncology Society

Convening hundreds of the leading Sarcoma experts is essential in advancing SARC's goals to better understand Sarcoma and improve patient outcomes.

2022 Goal
\$200,000

(two SARC membership/scientific conferences)



Advancing knowledge by bringing scientists together to **share** their findings

Investing in the **Future** of Sarcoma Research

PROGRAM 5

UNIFIED DATA SYSTEM – RESEARCH TISSUE, BLOOD IMAGING & DATA REPOSITORIES



2022 Goal
\$110,000

2022 Goal
\$75,000

2022 Goal
\$35,000

BIOSPECIMEN BANK

Our Biospecimen Bank is a “library” of Sarcoma tissue and blood collected to explore biomarkers, identify novel therapeutic targets, and make other translational discoveries.

Currently, there are 20,000+ cancer tissue and blood samples available in “the library” used by Sarcoma researchers to develop, test and validate concepts.

CLINICAL DATA REPOSITORY

SARC has established a vast repository of Sarcoma research data sets which includes essential clinical trial data acquired over the years from SARC studies, contributed by thousands of patients.

This data is used by Sarcoma researchers to develop new studies.

IMAGING REPOSITORY

SARC has compiled all radiographic imaging studies from our clinical trials into a data imaging repository. This bank of images is linked to clinical data and available to all Sarcoma investigators for further exploration and the generation of new ideas for Sarcoma research.

SARC is **motivated** to have our collection of tissues, blood, images, and data utilized to further research and understanding of Sarcoma

SARC Scientific Steering Committee



Karla Ballman, PhD
SARC Statistician
Professor of Biostatistics,
Chief of Biostatistics and
Epidemiology
Weill Cornell Medical College



Scott Okuno, MD
SARC Medical Officer
Professor of Oncology
Mayo Clinic




Sandra D'Angelo, MD
Associate Attending
Physician Member,
Immunotherapeutics Clinic
Memorial Sloan Kettering
Cancer Center



Shreyaskumar Patel, MD
Professor of Medicine
Medical Director,
Sarcoma Medical Oncology
The University of Texas
MD Anderson Cancer Center



Lara Davis, MD
Associate Professor of Medicine,
Sarcoma Program Director
Co-Leader, Knight Cancer Institute
Translational Oncology Program
Oregon Health & Sciences
University



Andrew Wagner, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Associate Chief Medical Officer
Medical Director, Adult
Ambulatory Oncology
Senior Physician, Center for
Sarcoma and Bone Oncology
Dana-Farber Cancer Institute




Jonathan Fletcher, MD
SARC Chief Scientific Officer
Associate Professor of Pathology,
Associate Professor of Pediatrics
Harvard Medical School



Steven Young
SARC President and CEO,
SARC Board of Directors

SARC Discovery/Translation Committee



Ping Chi, MD, PhD
Medical Oncologist
Memorial Sloan Kettering
Cancer Center



Seth Pollack, MD
Associate Professor;
Director, Sarcoma Program
Lurie Cancer Center
Northwestern University



Liz Demicco, MD, PhD
Associate Professor,
Department of Laboratory
Medicine and Pathobiology
University of Toronto



Christine Pratalis, MD
Associate Professor of Oncology,
Pediatrics & Cellular and
Molecular Medicine
Johns Hopkins University School
of Medicine



Jonathan Fletcher, MD
SARC Chief Scientific Officer
Associate Professor of Pathology,
Associate Professor of Pediatrics
Harvard Medical School



Andrew Wagner, MD, PhD
Associate Professor of Medicine
Harvard Medical School;
Associate Chief Medical Officer
Medical Director, Adult
Ambulatory Oncology
Senior Physician, Center for
Sarcoma and Bone Oncology
Dana-Farber Cancer Institute



Kevin Jones, MD, PhD
Leader, Sarcoma Disease Center;
Division Chief, Sarcoma,
Department of Orthopaedics;
Professor, Department of
Orthopaedics
Huntsman Cancer Center



Brigitte Widemann, MD
Senior Investigator
Chief, Pediatric Oncology Branch
National Cancer Institute
National Institutes of Health



Troy McEachron, PhD
Investigator
Pediatric Oncology Branch,
National Cancer Institute
National Institutes of Health




In Summary

SARC's unique ability to promote collaboration and unity among the Sarcoma research community through scientific rigor, credibility and efficiency ensures that things get done.

SARC is:

- an open, “one-stop” collaborative model connecting and coordinating the best scientific minds in Sarcoma against all types of this deadly cancer
- training the cadres of researchers needed today and tomorrow to achieve high-impact advances
- highly regarded for its track record of innovative clinical trials and operational excellence, and
- the steward and distributor of uniquely valuable Sarcoma research data, clinical images, and biospecimens



SARC is a one-stop resource
for Sarcoma expertise and facilitated collaborations



We
appreciate
your
support!

Thank You

We greatly appreciate the time you spent reading about SARC and exploring how you can partner with us to further our mission to achieve a cure for individuals impacted by Sarcoma.

Together, we can change the future through effective research and clinical trials, and ultimately improve the quality of life for those patients diagnosed with Sarcoma.

SARC Board of Directors

Ernest Conrad III, MD
SARC Chair
Professor, Department of
Orthopaedic Surgery
McGovern Medical School

Jonathan Fletcher, MD
SARC Chief Scientific Officer
Assoc. Professor of Pathology
Assoc. Professor of Pediatrics
Harvard Medical School

Eva Gallagher, PhD, RN, ANP-BC
SARC Secretary
VP, Head of Medical Affairs, Agios
Pharmaceuticals
Assist. Professor, Georgetown
University

Ann Graham
Founder and Executive
Director, MIB Agents
Osteosarcoma Alliance

Marlene Portnoy
Founder and Executive
Director, Desmoid Tumor
Research Foundation

Timothy Timmerman, Esq.
SARC Treasurer
Director, Tax Department
Cardinal Health

Andrew Wagner, MD, PhD
Assoc. Professor of Medicine,
Harvard Medical School
Assoc. Chief Medical Officer
Director, Adult Ambulatory Oncology
Dana-Farber Cancer Institute

Steven Young
SARC President and CEO



SARC
collaborating to cure sarcoma

Steven Young

President & Chief Executive Officer

syoung@sarctrials.org • (734) 930-7600

www.sarctrials.org